開示日時：2022/05/12 18:35:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.12 | 31,800 | -241,900 | -241,900 | -25.98 |
| 2019.12 | 131,000 | -176,200 | -176,200 | -17.75 |
| 2020.12 | 45,400 | -411,600 | -411,600 | -35.16 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 104.0 | 105.72 | 128.965 | – | – |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.12 | -258,000 | -232,300 |
| 2019.12 | -156,000 | -82,800 |
| 2020.12 | -296,000 | -278,900 |
※金額の単位は［万円］
▼テキスト箇所の抽出
To: All Concerned Parties May 12, 2022 Company Name: Solasia Pharma K.K. Representative: Yoshihiro Arai, President & CEO (Code number: Contact: Tel: URL: 4597, TSE Growth Section) Toshio Miyashita, CFO, Director 81-3-5843-8046 https://solasia.co.jp/en/ Solasia announces SP-03 episil® Business Tokyo, Japan, May 12, 2022 – Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai; “Solasia”), a specialty pharmaceutical company based in the Asian region, hereby announces that, as of today, there is a difference of opinion with Camurus AB (“Camurus”) regarding the continuity of the LICENSE AND DISTRIBUTION AGREEMENT for our development product SP-03 episil® business. At least for the time being, product supply of SP-03 episil® will be maintained. Solasia is currently engaging in discussions with Camurus to resolve this issue. ### 1
